MDS Pharma Services has named two experienced medical professionals to lead its late stage clinical trial management activities related to respiratory ailments and metabolic disorders.
Dr. Bernard Tisserand and Dr. Jonny L. Salyer have been named Executive Medical Directors for Respiratory Disorders and Metabolic Disorders, respectively. These therapeutic areas represent serious global public health concerns and are key areas of focus for MDS Pharma Services' customers.
Respiratory disorders include conditions such as asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and community acquired pneumonia (CAP), while metabolic disorders include diabetes, dyslipidemia, obesity and metabolic syndrome, which are defined as a cluster of conditions that damage the cardiovascular system.
In addition to respiratory and metabolic disorders, other areas of therapeutic focus for MDS Pharma Services include oncology, vaccines, and diseases of the cardiovascular and central nervous systems.